16 January 2019 - 11 Shevat 5779 - י"א שבט ה' אלפים תשע"ט
Chengdu Kanghong Pharma buys IOPtima E-mail

Bio Light Israeli Life Sciences Investments Ltd., which develops various ophthalmology products, announced the completion of a deal to sell its IOPtima subsidiary on 21 November.

In April, BioLight had reported a memorandum of understanding for an initial investment in the company with an option for acquisition, and the option is now being exercised. IOPtima manufactures and markets a surgical device for treatment of glaucoma.

The acquiring company is China-based Chengdu Kanghong Pharmaceutical Group, which is listed on the Shenzhen Stock Exchange at a US$6 billion market cap. The company works in the ophthalmology field, from R&D to marketing.

Please login or register to see the full article

Warning: Parameter 1 to modMainMenuHelper::buildXML() expected to be a reference, value given in /home/joomla789/domains/jewishtimesasia.org/public_html/libraries/joomla/cache/handler/callback.php on line 99
Jewish Times Asia is published by Jewish Times Asia Ltd. © Copyright 2019.
Material in the newspaper or on this site may not be used or reproduced in any form or in any way without permission from the editor.
While every effort has been made to ensure the content is true and accurate, the publisher is not responsible for any errors or omissions in the printed text.